Charlotte's Web Holdings (TSE:CWEB)
TSX:CWEB
Want to see TSE:CWEB full AI Analyst Report?
CWEB Stock Chart & Stats
C$0.28
>-C$0.01(-2.86%)
At close: 4:00 PM EST
C$0.28
>-C$0.01(-2.86%)
Day’s Range― - ―
52-Week RangeC$0.11 - C$1.33
Previous CloseN/A
Volume4.38K
Average Volume (3M)140.12K
Market Cap
C$94.76M
Enterprise ValueC$130.94M
Total Cash (Recent Filing)C$5.20M
Total Debt (Recent Filing)C$64.96M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Aug 06, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding160,605,900
10 Day Avg. Volume81,567
30 Day Avg. Volume140,116
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-28.04
Price to Sales (P/S)1.15
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)C$53.84M
Bulls Say, Bears Say
Bulls Say
Balance-sheet Cleanup (BAT)The BAT conversion plus $10M placement materially reduces interest burden and converts the largest liability to equity, improving liquidity and lowering near-term refinancing risk. This structural capital relief lengthens the runway and reduces fixed financial drag on operating cash flow.
Medicare CMMI Pilot AccessEligibility for CMMI pilot programs creates a durable institutional channel into value‑based care, enabling recurring, institutionally funded demand. Access to ~2M beneficiaries and ACO allocation mechanisms can provide predictable purchase volumes and a higher‑confidence commercial pathway versus retail alone.
Pharma Pathway Via DeFloriaAdvancing DeFloria into Phase II is a structural diversification toward regulated pharmaceuticals. Success could validate product science, unlock higher‑margin commercial opportunities, and grant exclusive manufacturing upside, shifting revenue mix away from commoditized retail CBD over the medium term.
Bears Say
Persistent Cash BurnSustained negative operating cash flow and free cash flow indicate ongoing cash burn that limits reinvestment capacity and forces dependence on external financing or asset sales. Over months, this constrains marketing, manufacturing scale, and increases dilution risk if structural improvements stall.
Negative Equity & High DebtNegative shareholders' equity combined with substantial debt materially weakens credit standing and reduces strategic flexibility. This stressed capital structure raises refinancing and covenant risk, limits ability to fund growth organically, and increases the likelihood of dilutive capital raises.
Regulatory Uncertainty RiskA potential federal restriction on hemp/THC would structurally shrink the addressable market and could invalidate existing formulations. This policy divergence with CMS guidance increases product, compliance, and inventory risk, and could slow institutional adoption despite Medicare pilot eligibility.
Charlotte's Web Holdings News
CWEB FAQ
What was Charlotte's Web Holdings’s price range in the past 12 months?
Charlotte's Web Holdings lowest stock price was C$0.10 and its highest was C$1.33 in the past 12 months.
What is Charlotte's Web Holdings’s market cap?
Charlotte's Web Holdings’s market cap is C$94.76M.
When is Charlotte's Web Holdings’s upcoming earnings report date?
Charlotte's Web Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 77 days.
How were Charlotte's Web Holdings’s earnings last quarter?
Currently, no data Available
Is Charlotte's Web Holdings overvalued?
According to Wall Street analysts Charlotte's Web Holdings’s price is currently Overvalued.
Does Charlotte's Web Holdings pay dividends?
Charlotte's Web Holdings does not currently pay dividends.
What is Charlotte's Web Holdings’s EPS estimate?
Charlotte's Web Holdings’s EPS estimate is -0.03.
How many shares outstanding does Charlotte's Web Holdings have?
Charlotte's Web Holdings has 160,605,900 shares outstanding.
What happened to Charlotte's Web Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Charlotte's Web Holdings?
Currently, no hedge funds are holding shares in TSE:CWEB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Charlotte's Web Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.45%
12-Months-Change
Fundamentals
Return on Equity
-275.39%
Trailing 12-Months
Asset Growth
-34.56%
Trailing 12-Months
Company Description
Charlotte's Web Holdings
Charlotte's Web Holdings, Inc. engages in farming, manufacturing, marketing, and selling hemp-derived cannabidiol (CBD) wellness products. The company's products categories include hemp extract oil tinctures, such as liquid products; gummies comprising sleep, stress, immunity, and exercise recovery products; and capsules, CBD topical creams, and lotions, as well as products for pets under the Charlotte's Web, CBD Medic, CBD Clinic, and Harmony Hemp brands. Its products contain naturally occurring phytocannabinoids, including CBD, cannabichromene, cannabigerol, cannabinol, terpenes, flavonoids, and other beneficial hemp compounds. The company distributes its products through retail outlets and health care practitioners, as well as online through its website. It has a collaboration between its CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program; and scientific collaboration with McLean Hospital. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Denver, Colorado.
CWEB Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized several transformative, strategic positives — a balance-sheet‑clearing BAT transaction with fresh capital, federal Medicare pilot eligibility (Substance Access BEI) allowing full‑spectrum CBD access into accountable care channels, meaningful clinical progress via DeFloria's Phase II clearance, substantial cost reductions (SG&A down ~21% YoY and ~44.5% over two years), and improved operating loss and margin runways. These positives are tempered by ongoing regulatory uncertainty (including a potential November 2026 hemp provision that could severely constrain the market), persistent net losses (Q4 net loss $11.4M; full‑year net loss ~$29.7M), a nonrecurring $1.3M inventory charge that depressed reported margins, and liquidity dependence on shareholder approval of the BAT transaction. On balance, the call conveyed constructive momentum and multiple high‑impact catalysts that materially improve the company’s strategic position, while acknowledging meaningful near‑term risks and the gradual timing of revenue realization from Medicare pilots.View all TSE:CWEB earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---